A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia

Gynecologic Oncology
Ivan Diaz-PadillaAmit M Oza

Abstract

A phase II study was performed to evaluate the efficacy and safety of single-agent RO4929097 (a gamma-secretase inhibitor) in patients with recurrent platinum-resistant ovarian cancer. Women with progressive platinum-resistant ovarian cancer treated with ≤2 chemotherapy regimens for recurrent disease were enrolled in this trial. Patients received oral RO4929097 at 20 mg once daily, 3 days on/4 days off each week in a three week cycle. The primary endpoint was progression-free survival (PFS) rate at the end of 4 cycles. Secondary objectives included assessment of the safety of RO4929097 and exploration of molecular correlates of outcome in archival tumor tissue and serum. Of 45 patients enrolled, 40 were evaluable for response. Thirty-seven (82%) patients had high-grade ovarian cancer. No objective responses were observed. Fifteen patients (33%) had stable disease as their best response, with a median duration of 3.1 months. The median PFS for the whole group was 1.3 months (1.2-2.5). Treatment was generally well tolerated with 10% of patients discontinuing treatment due to an adverse event. In high grade serous ovarian cancer patients, the median PFS trended higher when the expression of intracellular Notch (NICD) protein by im...Continue Reading

References

Apr 30, 1999·Science·S Artavanis-TsakonasR J Lake
Apr 17, 2004·The American Journal of Surgical Pathology·Anais MalpicaElvio G Silva
Nov 3, 2004·Cancer Research·Xing FanCharles G Eberhart
Aug 9, 2005·Trends in Cell Biology·Jean C Y Wang, John E Dick
Feb 21, 2006·Cancer Research·Max S WichaGabriela Dontu
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Feb 17, 2009·Developmental Cell·L-K Phng, Holger Gerhardt
Jul 31, 2010·The American Journal of Pathology·Joon Tae ParkTian-Li Wang
Jan 13, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Adrian M JubbHartmut Koeppen
Jan 29, 2011·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Gordon John Sampson RustinUNKNOWN Gynecological Cancer Intergroup
Apr 1, 2011·Proceedings of the National Academy of Sciences of the United States of America·Jocelyn M StewartLaurie E Ailles
Jul 15, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Adam D StegCharles N Landen
Dec 7, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Adam D StegCharles N Landen
Apr 25, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anthony W TolcherJennifer J Wheler
May 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ian KropPatricia Lorusso
May 9, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mrinal M Gounder, Gary K Schwartz
May 16, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jon C Aster, Stephen C Blacklow
Aug 14, 2012·Journal of Cellular Biochemistry·Nuzhat AhmedMichael Quinn
Sep 27, 2012·American Journal of Clinical Pathology·Mohammed Tanjimur RahmanKohji Miyazaki
Sep 29, 2012·Proceedings of the National Academy of Sciences of the United States of America·Shannon M McAuliffeDaniela M Dinulescu
Jan 12, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Susana Banerjee, Stanley B Kaye
Jan 24, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anne F SchottJenny C Chang
Aug 1, 2013·OncoTargets and Therapy·Roma Olsauskas-KuprysClodia Osipo
Oct 1, 2013·Pharmacology & Therapeutics·Naoko TakebeSherry X Yang
Apr 20, 2014·Cancer Research·Wei HuAnil K Sood
Nov 5, 2014·Journal of Ovarian Research·Jolijn W GroenewegBo R Rueda
Jan 23, 2015·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Ahmed Numan AlniaimiStephen Rose

❮ Previous
Next ❯

Citations

Dec 4, 2015·Nature Reviews. Rheumatology·Sander W TasZoltán Szekanecz
Jul 20, 2016·Cancer Treatment Reviews·A CarneroM E LLeonart
Oct 5, 2016·Expert Opinion on Drug Discovery·Roberta RosaRoberto Bianco
May 5, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R FerrarottoP Munster
Jan 17, 2019·Archives of Pharmacal Research·Eunae Sandra ChoJong In Yook
Feb 13, 2020·Signal Transduction and Targeted Therapy·Liqun YangHongjuan Cui
Aug 10, 2019·World Journal of Stem Cells·Fang-Yu DuGuo-Liang Chen
Jul 31, 2020·Signal Transduction and Targeted Therapy·Qiao WangXia Zhao
Jun 10, 2020·Cells·Sandra Muñoz-Galván, Amancio Carnero
Sep 20, 2017·Molecular Cancer Research : MCR·Katherine K SlemmonsCorinne M Linardic
Apr 17, 2020·Signal Transduction and Targeted Therapy·Liqun YangHongjuan Cui
Feb 20, 2021·Seminars in Cancer Biology·M CummingsN M Orsi
Apr 9, 2021·Life Sciences·Pawan Kumar Raghav, Zoya Mann
Oct 9, 2021·Journal of Cutaneous Pathology·Riyad N H SeervaiJonathan L Curry

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

© 2021 Meta ULC. All rights reserved